Literature DB >> 12297391

Mice vaccinated with the O-antigen of Francisella tularensis LVS lipopolysaccharide conjugated to bovine serum albumin develop varying degrees of protective immunity against systemic or aerosol challenge with virulent type A and type B strains of the pathogen.

J Wayne Conlan1, Hua Shen, Ann Webb, Malcolm B Perry.   

Abstract

The purpose of this study was to evaluate the efficacy of a vaccine consisting of the O-polysaccharide of the lipopolysaccharide (LPS) of Francisella tularensis chemically conjugated to bovine serum albumin. The results show that conjugation preserved both the antigenicity and immunogenicity of the polysaccharide moiety. Mice vaccinated with the glyco-conjugate, but not with BSA alone, were completely protected against an intradermal challenge with a highly virulent type B strain of F. tularensis, and partially protected against an aerosol challenge with the same strain. However, such vaccination failed to protect against an aerosol challenge with a virulent type A strain of the pathogen. The results suggest that the O-antigen of F. tularensis could be considered as a potential component of a subunit vaccine against type B, but not type A strains of F. tularensis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12297391     DOI: 10.1016/s0264-410x(02)00345-6

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  67 in total

1.  A Francisella tularensis live vaccine strain (LVS) mutant with a deletion in capB, encoding a putative capsular biosynthesis protein, is significantly more attenuated than LVS yet induces potent protective immunity in mice against F. tularensis challenge.

Authors:  Qingmei Jia; Bai-Yu Lee; Richard Bowen; Barbara Jane Dillon; Susan M Som; Marcus A Horwitz
Journal:  Infect Immun       Date:  2010-07-19       Impact factor: 3.441

2.  Detoxified endotoxin vaccine (J5dLPS/OMP) protects mice against lethal respiratory challenge with Francisella tularensis SchuS4.

Authors:  Stephen H Gregory; Wilbur H Chen; Stephanie Mott; John E Palardy; Nicholas A Parejo; Sara Heninger; Christine A Anderson; Andrew W Artenstein; Steven M Opal; Alan S Cross
Journal:  Vaccine       Date:  2010-02-17       Impact factor: 3.641

3.  Characterization of Francisella tularensis outer membrane proteins.

Authors:  Jason F Huntley; Patrick G Conley; Kayla E Hagman; Michael V Norgard
Journal:  J Bacteriol       Date:  2006-11-17       Impact factor: 3.490

4.  Role of the wbt locus of Francisella tularensis in lipopolysaccharide O-antigen biogenesis and pathogenicity.

Authors:  Catherine Raynaud; Karin L Meibom; Marie-Annick Lety; Iharilalao Dubail; Thomas Candela; Eric Frapy; Alain Charbit
Journal:  Infect Immun       Date:  2006-10-09       Impact factor: 3.441

5.  A heterologous prime-boost vaccination strategy comprising the Francisella tularensis live vaccine strain capB mutant and recombinant attenuated Listeria monocytogenes expressing F. tularensis IglC induces potent protective immunity in mice against virulent F. tularensis aerosol challenge.

Authors:  Qingmei Jia; Richard Bowen; Jacob Sahakian; Barbara Jane Dillon; Marcus A Horwitz
Journal:  Infect Immun       Date:  2013-02-25       Impact factor: 3.441

6.  Identification of an essential Francisella tularensis subsp. tularensis virulence factor.

Authors:  Aiping Qin; David W Scott; Jennifer A Thompson; Barbara J Mann
Journal:  Infect Immun       Date:  2008-11-03       Impact factor: 3.441

7.  Bronchus-associated lymphoid tissue (BALT) and survival in a vaccine mouse model of tularemia.

Authors:  Damiana Chiavolini; Javier Rangel-Moreno; Gretchen Berg; Kate Christian; Laura Oliveira-Nascimento; Susan Weir; Joseph Alroy; Troy D Randall; Lee M Wetzler
Journal:  PLoS One       Date:  2010-06-16       Impact factor: 3.240

8.  Identification, characterization and immunogenicity of an O-antigen capsular polysaccharide of Francisella tularensis.

Authors:  Michael A Apicella; Deborah M B Post; Andrew C Fowler; Bradley D Jones; Jed A Rasmussen; Jason R Hunt; Sayaka Imagawa; Biswa Choudhury; Thomas J Inzana; Tamara M Maier; Dara W Frank; Thomas C Zahrt; Kathryn Chaloner; Michael P Jennings; Molly K McLendon; Bradford W Gibson
Journal:  PLoS One       Date:  2010-07-06       Impact factor: 3.240

Review 9.  Working toward the future: insights into Francisella tularensis pathogenesis and vaccine development.

Authors:  Roger D Pechous; Travis R McCarthy; Thomas C Zahrt
Journal:  Microbiol Mol Biol Rev       Date:  2009-12       Impact factor: 11.056

10.  An improved vaccine for prevention of respiratory tularemia caused by Francisella tularensis SchuS4 strain.

Authors:  Chandra Shekhar Bakshi; Meenakshi Malik; Manish Mahawar; Girish S Kirimanjeswara; Karsten R O Hazlett; Lance E Palmer; Martha B Furie; Rajendra Singh; J Andres Melendez; Timothy J Sellati; Dennis W Metzger
Journal:  Vaccine       Date:  2008-08-08       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.